Serotonin in Medical Technology

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

... syndrome . LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly ... was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase ...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... The development of a potentially life-threatening serotonin syndrome may occur with use of SNRI products, ... and with drugs which impair metabolism of serotonin (including MAOIs). serotonin syndrome may include mental-status changes (e.g., ...

XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain

... into its Phase 2b study of Bicifadine -- a serotonin and norepinephrine reuptake inhibitor (SNRI) -- ... has a unique ratio of reuptake inhibition of serotonin versus norepinephrine, which differentiates it ... pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the ...

Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study

... were excluded from this study. About Cymbalta serotonin and norepinephrine in the brain and spinal cord ... is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate ... may be due to increasing the activity of serotonin and norepinephrine in the central nervous ...

Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration

... for an injury to heal.(ii) About Cymbalta serotonin and norepinephrine in the brain and spinal cord ... is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate ... may be due to increasing the activity of serotonin and norepinephrine in the central nervous ...

Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial

... inverse agonist, or inhibitor, of the 5-HT2A serotonin receptor. serotonin activation of the 5-HT2A receptor on platelets ... cardiovascular tissues, APD791 may curb these serotonin mediated effects in the clinical setting, thereby ...

Five Clinical Studies to Receive $2.5 Million Under Foundation's 2007 Clinical Discovery Program

... Dr. Albin will investigate the role of serotonin neurons in PD-related sleep-disordered breathing. He will visualize serotonin neurons using an advanced medical imaging ... of Neuroscience in London hypothesizes that serotonin neurons are responsible for levodopa-induced ...

FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder

... Cymbalta since approval. About Cymbalta serotonin and norepinephrine in the brain and spinal cord ... is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate ... may be due to increasing the activity of serotonin and norepinephrine in the central nervous ...

Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome

... acid (5-HIAA), a metabolite of serotonin and biomarker for serotonin production, was observed in subjects who received ... studies demonstrated that LX1031 lowers serotonin levels in the intestine without affecting levels ...

New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression

... debilitating condition." About Cymbalta serotonin and norepinephrine in the brain and spinal cord ... is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate ... may be due to increasing the activity of serotonin and norepinephrine in the central nervous system. ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... a novel single agent that represents the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is located in areas of the brain involved in the control of ...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

... a novel single agent that represents the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is located in areas of the brain involved in the control of ...

New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings

... addition of chromium histidinate to the diet significantly increased brain serotonin levels. Increased serotonin levels are known to improve mood and decrease carbohydrate cravings. ...

Key Protein May Lead to Faster Acting Anti-Depression Drugs

... vulnerability to depression. This new research shows that p11 activates a serotonin receptor in the brain known for producing rapid antidepressant response. ... Parkinson's Research Center scientists begun studying p11 because the serotonin system which is central to depression is connected to dopamine in ...

Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting

... to date in healthy volunteers, indicated that the drug candidate reduced serotonin levels in humans as predicted by Lexicon's mouse models and preclinical ... including severe diarrhea and abdominal discomfort. LX1032 acts to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the ...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

... and EuroQoL Questionnaire - 5 Dimension. About Cymbalta serotonin and norepinephrine in the brain and spinal cord are believed to both ... studies, Cymbalta is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate the activity of these ...

Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain

... and unemployment.(v,vi,vii,viii) About Duloxetine serotonin and norepinephrine in the brain and spinal cord are believed to both ... studies, Duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is believed to potentiate the activity of these ...

FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

... of seizures. The development of a potentially life-threatening serotonin syndrome may occur with use of SNRI products, including tapentadol, ... SNRIs, TCAs, MAOIs and triptans, and with drugs which impair metabolism of serotonin (including MAOIs). The most common adverse events (greater than ...

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

... oral and selective inverse agonist of the 5-HT2A serotonin receptor. serotonin activation of the 5-HT2A receptor on platelets and vascular smooth muscle ... to play an important role in events leading to thrombosis, and elevated serotonin levels have been associated with increased cardiovascular risk. Normally, ...

European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder

... of action in humans is not fully known, it is believed to affect both serotonin and norepinephrine/noradrenaline mediated nerve signalling in the brain ... studies, duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine/noradrenaline. Scientists believe its effect on pain ...

Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension

... can provide a significant therapeutic benefit in PAH by inhibiting excess serotonin signalling." The U.S. Orphan Drug Act is intended to assist and ... the blood vessels, which leads to PAH. Excessive proliferative effects of serotonin on the heart contribute directly to progression towards heart failure. ...

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007

... in vivo as an antidepressant. ITI-007 acts as a potent inhibitor of the serotonin transporter (SERT), a major target for most antidepressant drugs. To ... of bipolar disorders. ITI-007 also has nanomolar affinity for the serotonin transporter (SERT). ITI-007 has a much lower propensity than several ...

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722

... in vivo as an antidepressant. ITI-007 acts as a potent inhibitor of the serotonin transporter (SERT), a major target for most antidepressant drugs. To ... of bipolar disorders. ITI-007 also has nanomolar affinity for the serotonin transporter (SERT). ITI-007 has a much lower propensity than several ...

Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

... seen with other antipsychotic therapies. Behaviorally, ITI-007 inhibited serotonin induced head twitches. Additionally, ITI-007 was shown to have an affinity for the serotonin reuptake site, an activity that potentially may be beneficial in treating ...

DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947

... of antidepressant action, DOV 21,947 was more potent than Tofranil(R), a serotonin and norepinephrine reuptake inhibitor and the selective serotonin reuptake inhibitors Prozac(R) and Celexa(R). Because of its ability to ...

Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk

... School of Medicine released a study revealing that women using tamoxifen to prevent a recurrence of breast cancer who also use certain selective serotonin reuptake inhibitors (SSRI), for example Prozac(R) (fluoxetine), Paxil(R) (paroxetine) and Zoloft(R) (sertraline), have up to twice the chance of ...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

... validation of neurogenesis as a target for the treatment of mood disorders like depression, in contrast to the traditional focus on affecting serotonin function for antidepressant drug development," said lead investigator Maurizio Fava, M.D., vice chair, department of psychiatry at Massachusetts ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... has a unique chemical structure that differs from conventional and atypical antipsychotic agents. It possesses high affinities for dopamine D(2), serotonin 5-HT(7), 5-HT(2A), 5-HT(1A), and noradrenaline alpha(2C) receptors. Lurasidone exhibits little or no affinity for histamine H(1) or acetylcholine ...

New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer

... at how these drugs impact breast cancer recurrence rates when taken with tamoxifen. The antidepressants at issue are three widely used selective serotonin reuptake inhibitors (SSRIs), Prozac(R) (fluoxetine), Paxil(R) (paroxetine) and Zoloft(R) (sertraline), and are among a group of drugs known as CYP2D6 ...

Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia

... Dainippon Sumitomo Pharma Co., Ltd., lurasidone is a novel compound with a unique receptor-binding profile including high affinity for dopamine D(2), serotonin 5-HT(2A), 5-HT(7), 5-HT(1A), and noradrenalin alpha(2c) receptors. Lurasidone has low affinity for histamine H(1), and cholinergic M(1) receptors. ...

FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia

... and active control in patients with schizophrenia, as well as safety data from more than 3,000 patients. Fanapt(TM) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist, and belongs to the class of atypical antipsychotics. "The approval of Fanapt(TM) marks a new opportunity for many ...

March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots

... Medications, both antidepressants and anti-anxiety drugs, also can help. Among antidepressants, the first choice often is a selective serotonin reuptake inhibitor (SSRI). This category includes fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft) and citalopram (Celexa). Other ...

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... tested. At the highest dose tested (10 mg) we expect to have full occupancy of 5HT2A receptors while adding incremental amounts of D2 receptor and serotonin reuptake transporter (SERT) occupancy. This has been confirmed in an ongoing human Positron Emission Tomography (PET) study where we have ...

American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression

... behavioral therapy, physical activity, cardiac rehabilitation, antidepressant drugs or combinations of those treatments. -- Selective serotonin reuptake inhibitor (SSRI) treatment soon after a heart attack is considered safe, relatively inexpensive and may be effective for treating ...

MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development

... products, today announced the completion of pilot product development for its thin film formulation of escitalopram oxalate, a selective serotonin reuptake inhibitor. Escitalopram oxalate is indicated for depression and generalized anxiety disorders and is marketed under the brand name ...

Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies

... averaging results from the screening PSGs. About APD125 Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia work by activating the GABA-A receptor complex in the brain, causing a general suppressive ...

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder

... and total sleep time over 8 weeks in patients with co-morbid insomnia and major depressive disorder (MDD) who were administered a Selective serotonin Reuptake Inhibitor (SSRI) for depression. Ambien CR also improved sleep-related next-day functioning measures. This data was presented at the SLEEP ...

GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

... by substance P and mediated by neurokinin (NK-1) receptors that are highly concentrated in the brain. The peripheral pathway is stimulated by serotonin and mediated by 5-HT3 receptors located primarily in the gut.(7) NK-1 receptor antagonists like casopitant block substance P from binding to ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

... for at least 6 months.(1,2) Several classes of drugs have demonstrated efficacy in the treatment of GAD. Treatment typically includes selective- serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs); however, approximately 30 percent of patients do not achieve an ...

Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents

... of tricyclic antidepressants (TCAs) with Lexapro. SSRIs and SNRIs (including Lexapro) and other psychotropic drugs that interfere with serotonin reuptake may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin and other anticoagulants may add to the risk. ...